logo
logo

Trexbio Closes The Final Tranche Of $59 Million Series A Financing To Advance Innovation In Tissue Immunobiology For The Treatment Of Cancer And Inflammatory Diseases

Jun 22, 2021•about 4 years ago

Amount Raised

$59 Million

Round Type

series a

San Francisco

Description

TRexBio, a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, announced the successful close of the final tranche of a $59 million Series A financing. Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs. Investors include Eli Lilly and Company (Lilly), SV Health, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments.

Company Information

Company

T Rex Bio

Location

San Francisco, California, United States

About

TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us to identify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. TRexBio is headquartered in South San Francisco, California. For more information, please visit trex.bio or follow us on LinkedIn.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech